Your browser doesn't support javascript.
loading
Hematopoietic Cell Transplantation and Outcomes Related to Human Papillomavirus Disease in GATA2 Deficiency.
Parta, Mark; Cole, Kristen; Avila, Daniele; Duncan, Lisa; Baird, Kristin; Schuver, Bazetta Blacklock; Wilder, Jennifer; Palmer, Cindy; Daub, Janine; Hsu, Amy P; Zerbe, Christa S; Marciano, Beatriz E; Cuellar-Rodriguez, Jennifer M; Bauer, Thomas R; Nason, Martha; Calvo, Katherine R; Merideth, Melissa; Stratton, Pamela; DeCherney, Alan; Shah, Nirali N; Holland, Steven M; Hickstein, Dennis D.
Afiliação
  • Parta M; Clinical Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland. Electronic address: mark.parta@nih.gov.
  • Cole K; Nursing Department, Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • Avila D; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Duncan L; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Baird K; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Schuver BB; Office of the Clinical Director, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Wilder J; Clinical Research Directorate, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland.
  • Palmer C; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Daub J; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Hsu AP; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Zerbe CS; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Marciano BE; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Cuellar-Rodriguez JM; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Bauer TR; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Nason M; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland.
  • Calvo KR; Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland.
  • Merideth M; National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland.
  • Stratton P; Office of the Clinical Director, National Institute of Neurological Disease and Stroke, National Institutes of Health, Bethesda, Maryland.
  • DeCherney A; National Institute of Child Health and Development, National Institutes of Health, Bethesda, Maryland.
  • Shah NN; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Holland SM; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.
  • Hickstein DD; Immune Deficiency-Cellular Therapy Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Transplant Cell Ther ; 27(5): 435.e1-435.e11, 2021 05.
Article em En | MEDLINE | ID: mdl-33965189
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Infecções por Papillomavirus / Alphapapillomavirus / Deficiência de GATA2 Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Infecções por Papillomavirus / Alphapapillomavirus / Deficiência de GATA2 Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article